Canada markets closed

Burning Rock Biotech Limited (BNR)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
0.8070+0.0484 (+6.38%)
At close: 04:00PM EDT
0.7747 -0.03 (-4.00%)
After hours: 05:12PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.7586
Open0.7899
Bid0.5600 x 200
Ask1.0100 x 200
Day's Range0.7400 - 0.8199
52 Week Range0.5720 - 3.0400
Volume145,966
Avg. Volume50,977
Market Cap82.788M
Beta (5Y Monthly)0.23
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Burning Rock Publishes 2023 Annual Report on Form 20-F

    GUANGZHOU, China, April 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 29, 2024 it filed its Annual Report on Form 20-F for the year ended December 31, 2023 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F is available for viewing on the SEC website

  • GlobeNewswire

    Burning Rock Announces ADS Ratio Change

    GUANGZHOU, China, April 26, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will change the ratio of its American depositary shares (the “ADSs”) to Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS representing ten (10) Class A ordinary sh

  • GlobeNewswire

    Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results

    GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 31, 2023. 2023 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profita